Focus: Idorsia is a Swiss biotechnology company focused on small-molecule drugs in cardiovascular and psychiatric indications. The company is entirely dependent on QUVIVIQ (daridorexant) for revenue, which limits its market diversification.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Idorsia to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Idorsia
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Idorsia's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Idorsia's sole revenue driver; orexin receptor antagonist with multi-indication label expansion potential through Phase 4 trials in Alzheimer's disease.
Endothelin receptor antagonist in growth phase with Phase 3 data in resistant hypertension; significant revenue upside if labels expand or market adoption accelerates.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo